Intratumoral Heterogeneity Determines the Expression of mTOR-pathway Proteins in Prostate Cancer
Table 3
Uni- and multivariate Cox regression analyses for the association between immunostaining expressions of mTOR (model 1), p-mTOR (2), and 4E-BP1 (3) and biochemical recurrence.
Univariate HR (95% CI)
value
Model 1
value
Model 2
value
Model 3
value
mTOR, weak vs. strong staining
1.9 (0.9-4.0)
0.11
2.0 (1.1-4.2)
0.04
—
—
—
—
p-mTOR, weak vs. strong staining
1.8 (0.8-3.8)
0.12
—
—
1.1 (0.5-2.6)
0.74
—
—
4E-BP1, weak vs. strong staining
1.6 (0.7-3.4)
0.25
—
—
—
—
1.7 (0.8-3.8)
0.26
PSA (ng/ml)
1.1 (1.0-1.2)
0.01
1.1 (1.0-1.2)
0.04
1.0 (0.9-1.1)
0.09
1.1 (1.0-1.2
0.07
Gleason score, vs. <7
3.2 (1.1-9.2)
0.03
—
—
—
—
—
—
Pathological stage, pT3 vs. pT2
4.2 (1.9-9.0)
<0.01
3.8 (1.7-8.3)
<0.01
3.4 (1.5-7.9)
<0.01
3.8 (1.7-8.3)
<0.01
Positive margins, yes vs. no
3.7 (1.6-8.5)
<0.01
—
—
—
—
mTOR = mammalian target of rapamycin; p-mTOR = phosphorylated mammalian target of rapamycin; 4E-BP1 = 4 eukaryotic-binding protein 1; BCR = biochemical recurrence.
